Taken together, our findings firstly identified that targeting PTGDS promotes the ferroptosis in PTCL through regulating HMOX1-mediated iron metabolism, and highlighted novel therapeutic strategies to improve the efficacy of ferroptosis-targeted therapy in PTCL patients. The gene discussed is PTGDS; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.